PMID- 15864276
OWN - NLM
STAT- MEDLINE
DCOM- 20050519
LR  - 20220408
IS  - 1474-175X (Print)
IS  - 1474-175X (Linking)
VI  - 5
IP  - 5
DP  - 2005 May
TI  - ERBB receptors and cancer: the complexity of targeted inhibitors.
PG  - 341-54
AB  - ERBB receptor tyrosine kinases have important roles in human cancer. In 
      particular, the expression or activation of epidermal growth factor receptor and 
      ERBB2 are altered in many epithelial tumours, and clinical studies indicate that 
      they have important roles in tumour aetiology and progression. Accordingly, these 
      receptors have been intensely studied to understand their importance in cancer 
      biology and as therapeutic targets, and many ERBB inhibitors are now used in the 
      clinic. We will discuss the significance of these receptors as clinical targets, 
      in particular the molecular mechanisms underlying response.
FAU - Hynes, Nancy E
AU  - Hynes NE
AD  - Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 
      Basel, Switzerland. Hynes@fmi.ch
FAU - Lane, Heidi A
AU  - Lane HA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
EIN - Nat Rev Cancer. 2005 Jul;5(7):580
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Drug Delivery Systems
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Neoplasms/*drug therapy/*etiology
MH  - Receptor Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Receptor, ErbB-2/antagonists & inhibitors/immunology/*physiology
MH  - Signal Transduction/drug effects
RF  - 166
EDAT- 2005/05/03 09:00
MHDA- 2005/05/20 09:00
CRDT- 2005/05/03 09:00
PHST- 2005/05/03 09:00 [pubmed]
PHST- 2005/05/20 09:00 [medline]
PHST- 2005/05/03 09:00 [entrez]
AID - nrc1609 [pii]
AID - 10.1038/nrc1609 [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2005 May;5(5):341-54. doi: 10.1038/nrc1609.